Omega-3 for Men in the Major Heart Trials

Omega-3 for men has its strongest evidence in high triglycerides and raised heart risk, and the clearest heart benefit came from one prescription product. In a primary-prevention trial of 25,871 adults, fish oil did not lower major cardiovascular events or cancer.¹ Prescription icosapent ethyl lowered the risk of cardiovascular events by 25% in statin-treated patients with elevated triglycerides and heart disease or diabetes.² Omega-3 also lowers triglycerides and is linked with higher atrial fibrillation risk.^4,5 Your lipid panel and cardiovascular history decide which of these results applies to you.

Omega-3 Fish Oil in Generally Healthy Adults

The largest primary-prevention trial of fish oil found no effect on major heart events. The Vitamin D and Omega-3 Trial randomized 25,871 men aged 50 or older and women aged 55 or older in the United States.¹ Its vitamin D results are covered in vitamin D3 and K2. Participants took marine omega-3 fatty acids at 1 g per day or placebo, a trial dose and not a recommendation for you.¹

Over a median of 5.3 years, a major cardiovascular event occurred in 386 people on omega-3 and 419 on placebo, a hazard ratio of 0.92 whose confidence interval included no effect.¹ Cancer rates were also similar.¹ Total heart attacks were lower with omega-3 (hazard ratio 0.72), but that was a secondary end point and does not carry the weight of the main result.¹ The trial found no excess bleeding or other serious adverse events.¹

If you are a generally healthy man without a heart diagnosis or high triglycerides, this is the trial that describes you. It gives you no strong reason to expect fish oil to prevent a heart event. It does give you a reason to look at your own risk markers before you decide.

Prescription Icosapent Ethyl and the REDUCE-IT Trial

The strongest positive omega-3 result comes from a prescription drug in a high-risk group. Icosapent ethyl is a highly purified ethyl ester of eicosapentaenoic acid (EPA), one of the omega-3 fats in fish oil.² REDUCE-IT enrolled 8,179 patients on statins who had established cardiovascular disease, or diabetes with other risk factors, and fasting triglycerides of 135 to 499 mg/dL.²

Over a median of 4.9 years, the primary composite end point occurred in 17.2% of the icosapent ethyl group and 22.0% of the placebo group, a hazard ratio of 0.75.² Cardiovascular death was also lower (4.3% versus 5.2%).² Hospitalization for atrial fibrillation or flutter was higher with the drug (3.1% versus 2.1%).²

Vascepa (icosapent ethyl) is an FDA-approved prescription drug, first approved in the US in 2012.⁶ Its label indicates it alongside maximally tolerated statin therapy to reduce heart attack, stroke and related events.⁶ The indication covers adults with triglycerides of 150 mg/dL or higher and established cardiovascular disease, or diabetes plus 2 or more other risk factors.⁶ It is also indicated alongside diet for severe hypertriglyceridemia, defined on the label as 500 mg/dL or higher.⁶ If your labs and history match that profile, the prescription product is a conversation to have with your physician. An over-the-counter fish oil capsule is a different product.

The STRENGTH Trial and a Different Omega-3 Formula

A second high-risk trial used a different omega-3 product and found no benefit. STRENGTH randomized 13,078 statin-treated patients with high cardiovascular risk, high triglycerides and low HDL cholesterol to an EPA and DHA carboxylic acid formulation or corn oil.³

The trial was stopped early after an interim analysis showed a low probability of benefit. The primary end point occurred in 12.0% of the omega-3 group and 12.2% of the corn oil group.³ Gastrointestinal side effects were more common with omega-3 (24.7% versus 14.7%).³ The authors concluded that the findings do not support this formulation for reducing major cardiovascular events in high-risk patients.³

Omega-3 products are not interchangeable. A result from one purified prescription product does not transfer to another formula, and it transfers even less to a supplement bought off the shelf.

The Cochrane Review Across 86 Trials

The broadest look at omega-3 and the heart is the 2020 Cochrane review, which pooled 86 randomized trials with 162,796 participants.⁴ Increasing long-chain omega-3 had little or no effect on death from any cause, cardiovascular death, cardiovascular events, stroke or arrhythmia.⁴

The review found that long-chain omega-3 may slightly reduce coronary heart disease deaths and events, with low-certainty evidence. About 334 people would need to increase their intake to prevent one coronary death.⁴ The most consistent effect was on blood fats: long-chain omega-3 lowered triglycerides by about 15%, with high-certainty evidence.⁴

For you, that makes triglycerides the clearest reason to consider omega-3. If yours are normal, the heart-protection case is small. If they are high, the next question is what is driving them.

The Atrial Fibrillation Signal

Omega-3 treatment is linked with a higher risk of atrial fibrillation (AF), an irregular heart rhythm. A 2021 meta-analysis pooled 8 large outcome trials with 83,112 participants.⁵ AF occurred in 4.0% of people on omega-3 and 3.3% on control, a relative risk of 1.24.⁵

The association was modest in trials using 1 g a day or less (relative risk 1.12) and stronger in trials using more than 1 g a day (relative risk 1.51).⁵ Stroke risk did not rise.⁵ The authors noted that overall AF rates were low.⁵ The Vascepa label carries an AF warning and states that AF was more common in patients with a prior history of it.⁶ It also warns of increased bleeding, especially in people taking aspirin, clopidogrel or warfarin.⁶

If you have had AF, take a blood thinner, or have a fish or shellfish allergy, tell your physician before you start any omega-3 product.⁶ Those details change whether it fits your plan.

Prescription Omega-3 Compared With Fish Oil Supplements

Question	Prescription icosapent ethyl	Over-the-counter fish oil
FDA status	FDA-approved prescription drug6	Outside the Vascepa approval and label6
What it contains	Purified EPA ethyl ester2,6	EPA and DHA from fish oil, in doses that varied widely across trials4
Best trial result	25% lower risk of the main cardiovascular end point in high-risk, statin-treated patients2	No drop in major cardiovascular events in healthy adults1
Main safety signals	AF and bleeding warnings on the label6	AF risk rose with dose across 8 omega-3 outcome trials.5 No excess bleeding in the Vitamin D and Omega-3 Trial.1
Who it fits	Adults matching the label's triglyceride and risk criteria6	A physician's call based on your diet and labs
Verdict	The evidence-backed choice for high triglycerides with heart disease or diabetes risk	A triglyceride option for your physician to weigh

If your triglycerides are raised and you carry heart disease or diabetes risk, the prescription evidence is the one that applies. Your physician weighs that against your rhythm history and medications.

Triglyceride and Heart-Risk Labs That Guide the Decision

Whether omega-3 has a job in your plan comes down to your numbers. The Vascepa label tells prescribers to assess lipid levels first and to look for other causes of high triglycerides, such as diabetes, hypothyroidism or medications.⁶ A high triglyceride result is therefore a starting point for finding a cause, and a supplement is one possible response.

Your physician reads triglycerides with the rest of your cardiovascular picture. Your physician may also read lipoprotein(a), another cardiovascular risk marker, alongside your triglycerides. The heart disease in men guide covers the wider risk factors. For dietary fats, see good oils vs bad oils, and for the full supplement picture, see best supplements for men.

The Opt Take on Omega-3 for Men

Fish oil sold as a heart supplement is the same capsule for every buyer, and the trials found the clearest heart benefit for a prescription form in a high-risk group. A man with normal triglycerides and no heart diagnosis is in a different place from a man with high triglycerides on a statin. Your physician reads the pattern across your labs to tell which one you are.

At Opt Health, your initial panel covers 55+ biomarkers spanning hormones, inflammation, cardiovascular risk and more, taken at home or at a partner lab. A physician reviews the results with you 1:1, along with your existing conditions and current medications. Your plan can include prescriptions, peptides and supplements shipped from our pharmacy to your home.

Full labs and a physician consultation repeat every 3 to 4 months. Your physician compares your triglycerides and other markers with your baseline and adjusts the plan based on what changed.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.